Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
ONCY
Primary Symbol:
T.ONC
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and...
adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(216)
•••
13X2413
X
View Profile
View Bullboard History
Post by
13X2413
on Oct 31, 2024 9:43am
Noteable!?
This one looking worse and worse every day. Maybe you can give us some success stories about other companies.
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 30, 2024 5:44pm
RE:RE:RE:RE:ONCY's pelareorep upregulates PD-(L)1 / PD-L2
In metastatic breast cancer for example, certain patients cannot tolerate, do not respond, or quickly relapse on ADC therapy. In these instances a combination of pelareiorep + immune checkpoint
...more
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(188)
•••
pelaboost
X
View Profile
View Bullboard History
Comment by
pelaboost
on Oct 30, 2024 4:20pm
RE:RE:RE:ONCY's pelareorep upregulates PD-(L)1 / PD-L2
@Noteable. I have been thinking about this for a while from my lay perspective. Cost of treatment is increasingly a concern. Is it possible that pelareorep and a PD-L1 could stand in for ADCs in some
...more
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 30, 2024 1:41pm
RE:RE:ONCY's pelareorep upregulates PD-(L)1 / PD-L2
Also - upregulated levels of PD-L1 (High-PD-L1) are associated with high levels of tumor infilitrating lymphocytes (TiLs) and stem cell markers which in turm serve to remodel an immunosupressive TME
...more
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 30, 2024 1:32pm
RE:ONCY's pelareorep upregulates PD-(L)1 / PD-L2
https://stockhouse.com/companies/bullboard?symbol=oncy&postid=36289094
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 30, 2024 1:30pm
RE:RE:RE:RE:Development of PD-L1 Antibody Drug Conjugates (ADC)
October 2024 - In a significant development for cancer treatment, the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recently raised concerns over the use of
...more
(185)
•••
CMHarring218431
X
View Profile
View Bullboard History
Comment by
CMHarring218431
on Oct 30, 2024 10:05am
RE:RE:RE:RE:RE:3rd quarter
Should have read...is Not going to raise the price
(185)
•••
CMHarring218431
X
View Profile
View Bullboard History
Comment by
CMHarring218431
on Oct 30, 2024 10:03am
RE:RE:RE:RE:3rd quarter
No question, shorts and mm's are in cahoots here! Like someone said.... it doesn't matter if a buy is for 10,000 shares or 10 shares... they only move the needle by the same amount. It's
...more
(216)
•••
13X2413
X
View Profile
View Bullboard History
Comment by
13X2413
on Oct 30, 2024 10:02am
RE:RE:RE:Big Pharma seeking to curate the cancer treatment space
Big Pharma needs space? They can have Oncy's office space. Should be available soon. :)
(206)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Oct 29, 2024 11:22pm
RE:RE:RE:3rd quarter
Ole unnoteable and canuckfan remind of the used car salesman from Ketchum and cheatum used car lot.
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 29, 2024 4:45pm
RE:RE:Big Pharma seeking to curate the cancer treatment space
https://stockhouse.com/companies/bullboard?symbol=t.onc&threadid=36284061 https://finance.yahoo.com/news/oncolytics-targets-accelerated-approval-oncolytic-143358596.html
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 29, 2024 4:30pm
RE:Big Pharma seeking to curate the cancer treatment space
With all of the recent positive developments surrounding ONCY, and with an Accelerate Approval given the 'FDA nod', ONCY's acquisition is now more likely sooner than later.
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Post by
Noteable
on Oct 29, 2024 4:20pm
Big Pharma seeking to curate the cancer treatment space
Any Big Pharma seeking to curate that cancer I/O treatment space will eventually acquire ONCY. https://stockhouse.com/companies/bullboard?symbol=oncy&threadid=35837395
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Oct 29, 2024 2:37pm
RE:RE:RE:RE:RE:RE:Novartis US$2.9 Billion MorphoSys BET Inhibitor safety issue
Most colorectal cancer (CRC) patients are insensitive to immune checkpoint inhibitors (ICIs) due to the immunosuppressive tumor microenvironment (TME). Epigenetic factors such as the bromo-and
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden